Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine

A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Allogeneic Melanoma Cell-Loaded Dendritic Cell Vaccine
US brand name:	Uvidem
Code name:	IDD-3

autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine

Search NCI's Drug Dictionary